Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 7, 2013, Pages 768-775

  Kahloon, Rehan A ^a   Xue, Jianmin ^a   Bhargava, Arpit ^a   Csizmadia, Eva ^b   Otterbein, Leo ^b   Kass, Daniel J ^a   Bon, Jessica ^a   Soejima, Makoto ^a   Levesque, Marc C ^a   Lindell, Kathleen O ^a   Gibson, Kevin F ^a   Kaminski, Naftali ^a   Banga, Gunjan ^a   Oddis, Chester V ^a   Pilewski, Joseph M ^a   Sciurba, Frank C ^a   Donahoe, Michael ^a   Zhang, Yingze ^a   Duncan, Steven R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adaptive immunity; B cells; Interstitial lung disease; T cells

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; COMPLEMENT; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN 8; UNCLASSIFIED DRUG;

AGED; ALLELE; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOCYTE FUNCTION; LUNG BIOPSY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

AGED; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-4; INTERLEUKIN-8; LINEAR MODELS; LUNG; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84875864680     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201203-0506OC     Document Type: Article

References (49)

1. Campbell DA, Poulter LW, Janossy G, du Bois RM. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985;40: 405-411.
2. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, Soler P. Cutting edge: non-proliferating mature immune cells form a novel type of organizing lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006;176:5735-5739.
3. Zuo F, Kaminski N, Eugui E, Allard J, Hakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-6297.
4. Dall Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S. Study of immune complexes in broncholaveolar lavage fluids. Respiration 1988; 54:36-41.
5. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, et al. Elevation of anticytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000;178:171-179.
6. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, Gadgil A, George MP, Gibson KF, Choi AM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007;179:2592-2599.
7. Ogushi F, Tani K, Endo T, Tada H, Kawano T, Asano T, Huang L, Ohmoto Y, Muraguchi M, Moriguchi H, et al. Autoantibodies to IL- 1a in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 2001;48:181-189.
8. Kurosu K, Takiguchi Y, Okada O, Yumoto N, Sakao S, Tada Y, Kasahara Y, Tanabe N, Tatsumi K, Weiden M, et al. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J Immunol 2008;181:756-767.
9. Taillé C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:759-766.
10. Grigolo B, Mazzetti I, Borzì RM, Hickson ID, Fabbri M, Fasano L, Meliconi R, Facchini A. Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis. Clin Exp Immunol 1998;114:339-346.
11. Yang Y, Fujita J, Bandho S, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ishida T. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin Exp Immunol 2002;128:169-174.
12. Wallace WHH, Howie SM. Upregulation of tenascin and TGF-b production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen. J Pathol 2001;195:251-256.
13. Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, Ross P, Marsh CB. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 2006;67:284-297.
14. Lee SJ, Kavanaugh A. Autoimmunity, vasculitis and autoantibodies. J Allergy Clin Immunol 2006;117:S445-S450.
15. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012;32:1119-1136.
16. Pordeus V, Szyper-Kravitz M, Levy RA, Vaz NM, Shoenfeld Y. Infections and Autoimmunity: a panorama. Clin Rev Allergy Immunol 2008;34:283-299.
17. Erickson SB, Kurtz SB, Donadio JV, Holley KE, Wilson CB, Pineda AA. Use of combined plasmapharesis and immunosuppression in the treatment of Goodpasture's syndrome. Mayo Clin Proc 1979;54:714-720.
18. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009;48:968-971.
19. Martinu T, Howell DN, Palmer SM. Acute cellular rejection and humoral sensitization in lung transplant recipients. Semin Respir Crit Care Med 2010;31:179-188.
20. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, Wells AU, Brezoni EA. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012;40:641-648.
21. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
22. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-643.
23. Kotslanidis IE, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, Sotiriou I, Aidinis V, Margaritis D, Tsatalas C, et al. Global impairment of CD41CD251FoxP31 regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179: 1121-1130.
24. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, Valentine VG, Lindsay EK, George MP, Steele C, et al. CD28 downregulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS ONE 2010; 5:e8959.
25. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, Rosen GD, Rosas IO, Dacic S, Ocak I, et al. The HLA Class II allele DRB1 1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS ONE 2011;6:e14715.
26. Xue JM, Kahloon RA, Bhargava A, Banga G, Gochuico BR, Dacic S, Gibson KF, Kaminski N, Sciurba FC, Rosas IO, et al. Decreased survival of idiopathic pulmonary fibrosis patients with heat shock protein 70 autoreactivity [abstract]. Am J Respir Crit CareMed 2011;183:A4275.
27. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E, Zhang Y, Sciurba FC, Duncan SR. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:156-163.
28. Fu SM, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 2011;37:104-112.
29. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Immunol 2001;7:899-905.
30. Wisniewska M, Karlberg T, Lehtiö L, Johansson I, Kotenyova T, Moche M, Schüler H. Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B, and HSPA5/BiP/GRP78. PLoS ONE 2010;5:e8625.
31. Purcell AW, Todd A, Kinoshita G, Lynch TA, Keech CL, Gething MJ, Gordon TP. Association of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity. Clin Exp Immunol 2003; 132:193-200.
32. Abulafia-Lapid R, Gillis D, Yosef O, Atlan H, Cohen IR. T cells and autoantibodies to human HSP70 in Type 1 diabetes in children. J Autoimmun 2003;20:313-321.
33. Yokota S-I, Chiba S, Furuyama H, Fujii N. Cerebrospinal fluids containing anti-HSP70 autoantibodies from multiple sclerosis patients augment HSP70-induced proinflammatory cytokine production in monocytic cells. J Neuroimmunol 2010;218:129-133.
34. Yokota S-I, Seiji Minota S, Fujii N. Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 2006;18:573-580.
35. Lu MC, Lai NS, Yu HC, Huang HB, Hsieh SC, Yu CL. Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum 2010;62:1213-1223.
36. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;185:67-76.
37. Kallwellis-Opara A, Dorner A, Poller WC, Noutsias M, Kuhl U, Schultheiss HP, Pauschinger M. Autoimmune features in inflammatory cardiomyopathy. Clin Res Cardiol 2007;96:469-480.
38. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complexmediated neutrophil recruitment and tissue injury. Circulation 2009; 120:2012-2024.
39. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 2007;111:36-44.
40. Jang JY, Jeong JG, Jun HR, Lee SC, Kim JS, Kim YS, Kwon MH. A nucleic acid-hydrolyzing antibody penetrates into cells via caveolaemediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell Mol Life Sci 2009;66:1985-1997.
41. Monaco C, Andereakos E, Kiriakidis S, Feldman M, Paleolog C. T-cellmediated signaling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004;3:35-42.
42. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol. 2004;4:583-594.
43. Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-444.
44. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93.
45. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibodypositive interstitial lung disease. Arthritis Rheum 2009;60:2183-2192.
46. Duncan SR. Perspective: Clues, not conclusions. Nature 2012;489:S15.
47. Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 2003;5:160-167.
48. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009;4:e5134.
49. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066-1073.